Gå offline med appen Player FM !
Navigating treatment choices in high-risk early-stage melanoma - touchONCOLOGY
Manage episode 455979822 series 3389426
touchEXPERT OPINIONS for touchONCOLOGY
Listen to three leading experts in melanoma discuss the risk of recurrence in early-stage disease, evaluate the latest data for adjuvant and neoadjuvant therapies, and consider the role of emerging biomarkers for predicting recurrence and guiding treatment decisions.
The experts
- Dr Tina J Hieken, Mayo Clinic, Rochester, MN, USA
- Prof. Piotr Rutkowski, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland
- Dr Teresa Amaral, Tübingen University, Tübingen, Germany
This touchPODCAST is for healthcare professionals outside of the UK only
This activity is funded by an independent medical education grant from Merck & Co., Inc. and is jointly provided by USF Health and touchIME. touchIME is an EBAC® accredited provider.
For further information visit our website:
https://touchoncologyime.org/navigating_treatment_choices_in_high-risk_early-stage_melanoma
102 episoder
Manage episode 455979822 series 3389426
touchEXPERT OPINIONS for touchONCOLOGY
Listen to three leading experts in melanoma discuss the risk of recurrence in early-stage disease, evaluate the latest data for adjuvant and neoadjuvant therapies, and consider the role of emerging biomarkers for predicting recurrence and guiding treatment decisions.
The experts
- Dr Tina J Hieken, Mayo Clinic, Rochester, MN, USA
- Prof. Piotr Rutkowski, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland
- Dr Teresa Amaral, Tübingen University, Tübingen, Germany
This touchPODCAST is for healthcare professionals outside of the UK only
This activity is funded by an independent medical education grant from Merck & Co., Inc. and is jointly provided by USF Health and touchIME. touchIME is an EBAC® accredited provider.
For further information visit our website:
https://touchoncologyime.org/navigating_treatment_choices_in_high-risk_early-stage_melanoma
102 episoder
Alle episoder
×1 Management of neurofibromatosis: Optimizing treatment and care from childhood to adult life - touchONCOLOGY 37:37
1 Management of neurofibromatosis: Optimizing treatment and care from childhood to adult life - touchNEUROLOGY 37:38
1 Advancing the treatment of muscle-invasive bladder cancer: Updates on immunotherapy in the perioperative setting 38:15
1 Navigating treatment choices in high-risk early-stage melanoma - touchDERMATOLOGY 34:20
1 Navigating treatment choices in high-risk early-stage melanoma - touchONCOLOGY 34:19
1 Advances in IOL technology and power calculations: Updates and innovations from 2024 13:58
1 Supporting healing in epidermolysis bullosa: Innovations and new directions for care 18:55
1 Primary biliary cholangitis: Appraising the changing therapeutic landscape 35:31
1 Primary biliary cholangitis: Appraising the changing therapeutic landscape 35:31
1 touchMDT: Precision targeting of MET in NSCLC: A multidisciplinary approach - Discussion 4 13:46
1 touchMDT: Precision targeting of MET in NSCLC: A multidisciplinary approach - Discussion 3 16:05
1 touchMDT: Precision targeting of MET in NSCLC: A multidisciplinary approach - Discussion 4 13:46
1 touchMDT: Precision targeting of MET in NSCLC: A multidisciplinary approach - Discussion 3 16:05
1 touchMDT for touchRESPIRATORY - What impact could immune checkpoint inhibitors (ICIs) have on the management of patients with limited-stage small cell lung cancer (LS-SCLC)? 15:14
1 touchMDT for touchRESPIRATORY - What are the key data for immune checkpoint inhibitors (ICIs) in the treatment of limited-stage small cell lung cancer (LS-SCLC)? 13:57
Velkommen til Player FM!
Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.